INTRODUCTION
Hyperglycemia may be observed at admission in patients with acute
myocardial infarction, independently of prior history of diabetes,
and is associated with an increase in mortality.1,2 The
increased mortality may be explained by larger infarct size and a
higher rate of heart failure and cardiogenic shock in that
population.3-5
In
some patients, elevated glucose levels may simply be a marker of
preexisting but as yet undetected disease, type 2 diabetes or
glucose intolerance,6 leading to an increase in
lipolysis and an excess of circulating free fatty acids, more
severe myocardial damage, and even more severe coronary
disease.5,7-10
Little is known about the role of hyperglycemia at admission in
patients with acute coronary syndrome, since only a few studies
have analyzed this marker in the population of patients with
non-ST-segment elevation myocardial infarction and unstable angina,
and in those that have, the follow-up period has been limited. Even
less is known in Latin American populations, as diagnosis of
infarction is often delayed and glucose levels may be just another
simple marker in this situation. This study addressed the
hypothesis that patients with acute coronary syndrome and increased
glucose levels show worse long-term outcome.
The
aim of the study was to analyze the long-term prognostic value of
glucose concentration at admission in patients with acute coronary
syndrome.
METHODS
Population
A
prospective observational study was performed in a population of
565 consecutive patients admitted between December 1997 and
December 2001 to the Coronary Care Unit of the Instituto de
Cardiología, Corrientes, Argentina, with a diagnosis of
acute coronary syndrome within 24 hours of the onset of
symptoms.
Inclusion Criteria
1. Acute coronary syndrome, defined as typical precordial pain
for at least 20 minutes along with the presence of 1 or more of the
following conditions: new or presumably new ST-segment deviation,
altered enzyme levels (creatine kinase MB isoenzyme [CK-MB] level
above the reference limit in 2 or more samples obtained within a
period of more than 6 hours and/or troponin T≥
0.02 ng/mL).
2. Acute myocardial infarction, defined as the presence of at
least 2 of the following 3 conditions: a) appearance of new
Q waves, b) CK-MB levels above the reference limit, and
c) precordial pain lasting at least 30 minutes. According to
the above criteria, the remaining patients were considered to have
unstable angina.
Exclusion Criteria
Admission more then 24 hours after onset of symptoms, cardiogenic
shock, acute pulmonary edema, suspected myocarditis, pulmonary
thromboembolism, congenital disease, dilated cardiomyopathy,
cardiac hypertrophy, valve disease or pericardial disease, and
difficulty in completion of follow-up.
Study Protocol
The
study protocol was approved by the Department of Research and
Teaching of our institution. Patients were informed regarding
inclusion in the study and provided signed consent.
All
patients were admitted to the coronary care unit, where a full
medical history was taken along with a physical examination,
12-lead electrocardiogram (ECG) at admission and 2 hours after
reperfusion therapy in those patients in whom ST-segment elevation
was observed, chest radiograph at admission and 24 hours later,
analysis of enzyme concentrations (CK, CK-MB) at admission, 2 hours
after admission or reperfusion therapy, at 6, 12, and 24 hours, and
then every 24 hours until enzyme concentrations returned to normal,
and concentrations of troponin T as a marker of myocardial necrosis
at admission.
Final diagnosis was acute myocardial infarction (AMI) in 56% of
patients (n=317) and unstable angina in 44% (n=248).
Definitions
- Hyperglycemia: The population was split into 2 groups
according to the cut point obtained from the receiver operating
characteristics (ROC) curve to predict mortality. Group 1 and group
2 contained patients with glucose concentrations of
≥
128 mg/dL, and
<128 mg/dL, respectively.
- Diabetes: presence of fasting glucose concentrations >126
mg/dL, diagnosed prior to admission.
- Q-wave infarction: defined after 24 hours according to the
presence of new Q waves in the V1-V3 leads or the development of Q
waves ≥
0.03 seconds in leads I, II, aVL, aVF, V4, V5, and
V6.11
- Non-Q-wave infarction: considered in the absence of new Q
waves in the ECG 24 hours after admission. It should be noted that
the old definition of infarction was used.
- Heart failure: defined by the presence of typical symptoms,
rales, S3 gallop, and evidence of pulmonary congestion in the chest
radiograph (flow redistribution, interstitial edema, and/or
alveolar edema), necessitating the use of intravenous diuretics,
vasodilators, and/or inotropic drugs.
- Mortality: all-cause death was calculated at the end of
follow-up.
Follow-Up and Endpoints
The
follow-up period lasted until 6 months after inclusion of the last
patient. Follow-up was performed using hospital medical records and
patients were assessed in the ischemic heart disease clinic (82%)
or by their cardiologist (13%); the remaining 5% were contacted by
telephone or through their primary care physician. The mean
follow-up period was 42 (9) months.
Hospital Treatment
Following admission, most patients received oral aspirin (100-325
mg/day). Patients with ST-segment elevation admitted in the 12
hours following onset of symptoms were treated by primary
angioplasty or with thrombolytic drugs. Intravenous nitroglycerin
was administered in 92% of patients and, in the absence of
contraindications, intravenous or oral β
-blockers and angiotensin
converting enzyme inhibitors (ACEI) were also
prescribed.
Statistical Analysis
A
ROC curve was constructed to determine the best cut point for
glucose concentration in the prediction of death during follow-up;
using this method, hyperglycemia was classified as a glucose
concentration ≥
128 mg/dL. The characteristics of the patients with
glucose levels greater than or equal to and below the cutoff were
compared by χ
&SUP2; test for qualitative variables and the results
were expressed as percentages. Quantitative variables were
expressed as means (SD) and analyzed using the Student t
test for normally distributed variables and the Mann-Whitney U test
for variables that were not normally distributed. Two Cox
proportional hazards models were constructed to identify
independent predictors of mortality during follow-up. The following
variables, which were significant in the univariate analysis, were
included in both models: male sex, systolic blood pressure, heart
rate, and troponin-T level at admission, diagnosis of infarction,
and heart failure during hospital stay, and in addition, glucose
concentration was included as a qualitative variable with a cutoff
of ≥
128
mg/dL (model 1) and as a quantitative variable with increments of
10 mg/dL (model 2). Differences were considered statistically
significant when P<.05. Kaplan-Meier survival analysis
was applied and log-rank tests were used to compare curves.
Analysis was performed using the statistical package SPSS 10.0 for
Windows (SPSS Inc, Chicago, Illinois, USA). Eleven patients were
lost to follow-up.
RESULTS
Patient Characteristics
The
general characteristics of the study population are shown in Table
1. The mean glucose level at admission was 143 (77) mg/dL. A ROC
curve was constructed to determine the best cut point for
prediction of mortality during follow-up. The area under the curve
was 0.67 (95% confidence interval [CI], 0.60-0.75) (Figure 1). A
total of 208 patients (36.8%) had glucose levels ≥
128 mg/dL at admission
(group 1); the remaining patients made up group 2.
Figure 1.
Receiver operating characteristic
(ROC) curve for prediction of death at 4-year follow-up. ROC curve
for glucose level (area below the curve, 0.67; 95% confidence
interval, 0.60-0.75); cut point, 128 mg/dL; sensitivity, 85%;
specificity, 62%.
The
mean age was similar in both groups (63.1 [11.5] vs 61.2 [12.5]
years, P=.76). Among the demographic characteristics of the
patients at admission, a higher proportion of diabetes and
hypertension, and a larger number of women were found in group 1
(Table 1).
When clinical characteristics were analyzed, it was observed that
group 1 had more hypertension and tachycardia at admission, with a
larger number of affected coronary vessels, higher concentrations
of markers of myocardial necrosis, and a lower left ventricular
ejection fraction (Tables 2 and 3).
Treatment
In
this series of patients included in the 24 hours following onset of
symptoms, reperfusion therapy with thrombolytic drugs was used to a
similar extent in both groups. However, there was greater use of
primary angioplasty in patients with infarction in the
hyperglycemic group. The patients in group 1 were more often
prescribed ACEI, while β
-blockers were used more often
in group 2 (Table 4).

Predictors of Mortality and Analysis of Survival
Mortality during follow-up was 9.7%. Mortality was 3 times higher
in patients with glucose levels ≥
128 mg/dL (16.1% vs 4.7%;
P<.0001). Heart failure was developed during the period of
hospital admission in 12.7% of the population, with a higher
proportion in group 1 (21.4% vs 6%, P<.001) (Table
5).

The
following variables were independent predictors of mortality at
admission (Table 6, model 1): a glucose level ≥
128 mg/dL (hazard ratio
[HR], 2.41; 95% CI, 1.11-5.10), systolic blood pressure (HR, 0.97;
95% CI, 0.96-0.99), troponin T (HR, 4.88; 95% CI, 2.66-8.97), and
development of heart failure (HR, 1.04; 95% CI, 1.01-1.06). A 10-mg
increase in glucose level was associated with an increase in the
risk of death of 2.56 (95% CI, 1.12-5.32) (Table 6, model
2).
The
actuarial survival at 4 years was 40% and 77% in groups 1 and 2,
respectively (log-rank tests, P<.001) (Figure 2).
Follow-up was completed in 98% of patients, with a mean period of
42 (6) months.
Figure 2.
Kaplan-Meier survival curves for
groups 1 and 2.
DISCUSSION
In
this study, undertaken in an unselected population of patients with
acute coronary syndrome admitted to hospital in the 24 hours
following the onset of symptoms, glucose levels ≥
128 mg/dL, present in
more than a third of the population, were associated with an
independent increase in the risk of long-term mortality.
Hyperglycemia and Stress
It
is known that stress during acute infarction can lead to increased
glucose levels in the first few hours.4,5 Excessive
secretion of catecholamines causes, in addition to signs and
symptoms, an increase in cardiac oxygen consumption due to the
release of fatty acids. This favors glycogen breakdown and
contributes to an increase in glucose levels that, in association
with increased concentrations of glucagon and cortisol, leads to a
reduction in glucose tolerance and reduced myocardial
contractility. These changes are associated with a greater
incidence of deleterious effects such as no-reflow
phenomenon3,12,13 and heart failure during the period of
hospital admission.5 Stress hyperglycemia may be an
indicator of more extensive myocardial damage, which would be
reflected in increased concentrations of markers of myocardial
necrosis, with or without more extensive coronary
disease14,15 and worse prognosis.16-20 The
results of this study confirm those findings, given the observed
increase in the level of those markers.
Hyperglycemia as a Predictor of Mortality
In
this study, we observed that hyperglycemia at admission was
associated with a 2.41-fold increase in the risk of mortality in
patients with acute coronary syndrome. Most studies have been
undertaken in populations of patients with acute ST-segment
elevation myocardial infarction, in whom an increase in mortality
has been demonstrated along with the development of heart failure,
cardiogenic shock, and arrhythmias.5,9 However, this
unselected patient series also included non-ST-segment elevation
infarctions and high-risk unstable angina. Elevated glucose
concentrations have been independently associated with negative
outcome.5,20-24 In a previous study, we observed that
for each gram per liter increase in the glucose level there was a
1.7-fold increase in the risk of death during follow-up in patients
with acute infarction.11 Another interesting observation
in this study was that while 27.8% of the total population had a
history of diabetes, the definition proposed for hyperglycemia at
admission allowed detection of 36.8% of cases, almost 10% higher in
the overall population. Nowadays, it is known that recent onset
diabetes represents a high risk and that its presence is associated
with similar risk to that of previous
infarction.25
Patients with hyperglycemia more often suffer heart failure during
the period of hospital admission, ref lecting greater impairment of
the cardiac muscle, a lower ejection fraction, increased release of
markers of myocardial necrosis, and more severe coronary
disease.26,27 We believe that it is important to have
access to an appropriate parameter for the identification of left
ventricular dysfunction at the time of presentation of acute
coronary syndrome, as well as for the detection of potentially
reversible myocardial dysfunction that may benefit from
revascularization; this may facilitate the earliest possible
initiation of treatment to prevent
remodeling.28
An
increased troponin level at admission was shown to be a prognostic
marker in patients with or without ST-segment elevation. A
metaanalysis of 7 clinical trials and 19 cohort studies showed that
patients with positive results for troponin had higher mortality,
with a 3-fold to 8-fold increase in the risk of death.29
In patients with ST-segment elevation, increased troponin levels at
admission have been associated with increased mortality, as well as
with greater development of heart failure and cardiogenic shock at
30-day follow-up.30 The increased mortality may be
simply a function of the longer duration of symptoms, the presence
of prior silent ischemic events that caused troponin release, or
greater myocardial vulnerability.31 In out study,
elevated troponin T at admission was a much better prognostic
marker than hyperglycemia, with more than 4 times the risk of death
during follow-up for every nanogram increase per
deciliter.
Hypotension at admission was also a prognostic marker: for each 1
mm Hg reduction in blood pressure the risk increased by
2.2%.
Other studies have shown that hyperglycemia is an indicator of
worse long-term outcome.6,7 Bolk et al4
reported an overall mortality of 19.3% at 1-year follow-up in an
unselected population of 336 consecutive patients with AMI, and
that rate increased to 44% in patients with glucose levels greater
than 11.1 mmol/L. In our study, patients with glucose levels
≥
128 mg/dL
showed worse survival at 4-year follow-up (40% compared with 77%)
and if we look carefully at the survival curves we see that they
separate initially during the period of hospitalization and that
the divergence is more marked after 18 months. This finding
indicates that elevated glucose levels at admission allow selection
of a group of patients at high clinical risk.
Limitations
Despite showing data from the "real world," the study does not
provide information on the treatment provided during hospital stay
in patients with hyperglycemia. In addition, glucose level was not
monitored periodically during hospital stay. The inclusion of acute
coronary syndromes up to 24 hours following onset of symptoms may
encompass various initial therapeutic strategies, which may
influence long-term prognosis.
Clinical Implications
The
results of this study show that in patients with acute coronary
syndromes hyperglycemia (cut point, ≥
128 mg/dL) allows
identification of a group of individuals at high risk of adverse
events during follow-up and lower survival at 4 years. The clinical
usefulness of these findings should be complemented with the
implementation of a diet low in carbohydrates, provision of insulin
during the acute event,32-36 as shown in the DIGAMI
study,32 and with the use of antithrombotic drugs such
as clopidogrel and statins, and invasive strategies such as primary
angioplasty, and early revascularization for unstable angina, or
non-Q-wave infarction.37-40
It
is important to remember that through this simple method, available
in any hospital, it is possible to identify at-risk individuals at
admission, allowing the best strategies possible to be offered or
for the patient to be referred to another hospital.
Other possible changes in the future would consist of early
recognition of hyperglycemia and the application of dietary
measures and insulin treatment,41,42 since optimization
of treatment for diabetes and glucose intolerance could improve
cardioprotection and reduce morbidity and mortality in these
syndromes.13
CONCLUSIONS
In
patients with acute coronary syndrome, hyperglycemia at admission
(cut point ≥
128 mg/dL) is associated with an increase in long-term risk
that, in addition, is a strong independent predictor.
Correspondence: Dra. S.M. Macín.
Unidad de Cuidados Intensivos Coronarios.
Instituto de Cardiología Juana F. Cabral.
Bolívar, 1334. 3400 Corrientes. Argentina.
E-mail: stellam@gigared.com or macinucic@hotmail.com
Manuscript received January 5, 2006.
Accepted for publication September 14, 2006.
References
1. Klamann A, Sarfert P, Schulte G, Launhardt V, Schemiegel W, Nauck MA. Myocardial infarction in diabetic versus non-diabetic subjects: relation of survival and infarct size following therapy with sulfonylurea (glibenclamide). Eur Heart J. 2000;21:220-9.[Medline]
2. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes. Diabetes Care. 2005;28:2551-3.[Medline]
3. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41:1-7.[Medline]
4. Bolk J, van der Ploeg T, Coronel JH, Arnold AE, Sepers J, Uman VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79:207-14.[Medline]
5. Capes S, Hunt D, Malmberg K, Gerstein H. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773-8.[Medline]
6. Ceriello A. Acute hyperglycaemia: a new risk factor during myocardial infarction. Eur Heart J. 2005;26:328-31.[Medline]
7. Nazneen N, Cowden E, Pearce N, Gardner M, Merry H, Cox J. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748-54.
8. Kosiborod M, Rathore S, Inzucchi S, Masoudi F, Wang Y, Havranek E. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction. Circulation. 2005;111:3078-86.[Medline]
9. Suleiman M, Hammerman H, Boulos M, Kapeliovich M, Suleiman A, Agmon Y, et al. Fasting glucose is an important independent risk factor for 30 day mortality in patients with acute myocardial infarction. Circulation. 2005;111:754-60.[Medline]
10. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-88.[Medline]
11. Macín SM, Perna ER, Augier N, Cialzeta J, Farías EF, Fontana M, et al. Características clínicas y evolución a largo plazo de pacientes con insuficiencia cardiaca como complicación del infarto agudo de miocardio. Rev Esp Cardiol. 2005;58:789-96.[Medline][Artículo]
12. Lopaschuk G, Stanley W. Glucose metabolism in the ischemic heart. Circulation. 1997;95:313-5.[Medline]
13. Taegtmeyer H, McNulty P, Young M. Adaptation and maladaptation of the heart in diabetes: Part I. General concepts. Circulation. 2002;105:1727-33.[Medline]
14. Monteiro P, Goncalves L, Providencia LA. Diabetes and cardiovascular disease: the road to cardioprotection. Heart. 2005;91:1621-5.[Medline]
15. Bartnik M, Malmberg K, Ryden L. Managing heart disease diabetes and the heart: compromised myocardial function-a common challenge. Eur Heart J. 2003;5 Suppl B:33-41.
16. Bolk J, van der Ploeg T, Cornel J, Arnold A, Sepers J, Umans V. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79:207-14.[Medline]
17. Williams S, Goldfine A, Timimi F, Ting H, Roddy M, Simonson D, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-701.[Medline]
18. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. On behalf of the ICONS Investigators. J Am Coll Cardiol. 2002;40;1748-54.[Medline]
19. Stentz F, Umpierrez G, Cuervo R, Kitabchi A. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-86.[Medline]
20. Chaudhuri A, Janicke D, Wilson M, Tripathy D, Garg R, Bandyopadhyay A, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST segment elevation myocardial infarction. Circulation. 2004;109:849-54.[Medline]
21. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-4.[Medline]
22. Marfella R, Siniscalchi M, Esposito K, Sellitto A, de Fanis U, Romano C, et al. Effects of stress hyperglycemia on acute myocardial infarction. Diabetes Care. 2003;26:3129-35.[Medline]
23. Jagasia D, Whiting J, Concato J, Pfau S, McNulty P. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation. 2001;103:1734-9.[Medline]
24. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL, and ICONS Investigators. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748-54.
25. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari J, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005;48:2519-24.
26. Wu A, Parsons L, Every N, Bates E. Hospital outcome in patients presenting with congestive heart failure complicating acute myocardial infarction. A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389-94.[Medline]
27. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction: a review. Am J Med. 2002;113:324-30.[Medline]
28. Dargie H. Heart failure post-myocardial infarction: a review of issues. Heart. 2005;91 Suppl II:3-6
29. Heidenreih PA, Alloggiamento T, Melsop K, McDonald KM, Go A, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol. 2001;38:478-85.[Medline]
30. Magnus Ohman E, Armstrong PW, White HD, Granger CHB, Wilcox RG, Douglas Weaver W, et al. Risk stratification with a point of care cardiac troponin T test in acute myocardial infarction. Am J Cardiol. 1999;84:1281-6.[Medline]
31. Bueno, H. Prevención y tratamiento de la cardiopatía isquemica en pacientes con diabetes mellitus. Rev Esp Cardiol. 2002;55:975-86.[Medline][Artículo]
32. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.[Medline]
33. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais, Xavier D, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATEECLA Randomized Controlled Trial. JAMA. 2005;293:437-46.[Medline]
34. Wang P, Chatman J. Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metabolism. 2004;286:E725-36.
35. van der Horst I, Zijlstra F, van't Hof A, Doggen C, de Boer M, Suryapranata H, et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;42:784-91.[Medline]
36. Bloomgarden Z. Inpatient diabetes control. Diabetes Care. 2004;27:2272-7.[Medline]
37. Giuliano R, Branunwald E. The year in non-ST-Segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005;46:906-19.[Medline]
38. Schwartz GG, Olsson AG. The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol. 2005;96:45F-53F.[Medline]
39. de Winter R, Windhausen F, Coronel JH, Dunselman PHJM, Janus CH, Bendermacher PEF, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-104.[Medline]
40. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. COMIT (Clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005;366:1622-32.[Medline]
41. Zamora A, Marrugat J. Pronóstico de los pacientes diabéticos con cardiopatía isquémica. Rev Esp Cardiol. 2002;55:751-62.[Medline][Artículo]
42. Jiménez-Navarro M, Curiel E, Hernández García J, Briales J, Domínguez Franco A, Gómez Doblas J, et al. Influencia de la diabetes mellitus en los resultados clínicos tras revascularización coronaria percutánea. Rev Esp Cardiol. 2002;55:365-71.[Medline][Artículo]